Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +17.95%
#2 clBTC clBTC +12.17%
#3 OpenEden OpenEden +11.49%
#4 Wrapped Ether (Mantle Bridge) Wrapped Ether (Mantle Bridge) +8.73%
#5 Not in Employment, Education, or Training Not in Employment, Education, or Training +8.41%
#6 Mantle Staked Ether Mantle Staked Ether +8.34%
#7 Palladium Network Palladium Network +7.82%
#8 Prom Prom +6.59%
#9 Zest Protocol Zest Protocol +6.19%
#10 EfficientFrontier EfficientFrontier +4.43%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Synairgen plc Synairgen plc

Synairgen plc

SNG
Rangering i aksjer #40400
Synairgen plc specializes in the research and development of pharmaceutical... Synairgen plc specializes in the research and development of pharmaceutical treatments for various respiratory conditions. Its product pipeline includes SNG001, an inhaled interferon beta currently being developed for COVID-19. The company is also advancing an inhaled form of interferon beta (IFN-ß) through Phase II clinical trials for the management of asthma triggered by common colds and influenza, as well as for the treatment or prevention of chronic obstructive pulmonary disease. Furthermore, Synairgen is developing a LOXL2 inhibitor intended for treating idiopathic pulmonary fibrosis (IPF). To support the development of this LOXL2 inhibitor, the company maintains a licensing and collaboration agreement with Pharmaxis Ltd. Synairgen plc was established in 2004 and is headquartered in Southampton, United Kingdom.
Aksjekurs
$0.01292666
Sist synkronisert: 2025-04-08
Markedsverdi
$157.54K
Endring (1 dag)
6.84%
Endring (1 år)
0.00%
Land
GB
Handel Synairgen plc (SNG)

Kategori

Healthcare
Antall utestående aksjer for Synairgen plc (SNG)
Antall utestående aksjer per June 2024: 201.38M
Ifølge Synairgen plc sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 201.38M. Ved slutten av December 2022 hadde selskapet 201.36M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Synairgen plc (SNG) fra 2004 til 2026
Utestående aksjer ved utgangen av hvert år
År Utestående aksjer Endre
2026 (TTM) 201.38M 0.00%
2023 201.38M 0.01%
2022 201.36M 0.46%
2021 200.44M 36.24%
2020 147.12M 33.64%
2019 110.09M 15.56%
2018 95.26M 1.15%
2017 94.18M 2.48%
2016 91.90M 0.64%
2015 91.32M 3.77%
2014 88.00M 16.35%
2013 75.64M 4.37%
2012 72.47M 19.66%
2011 60.56M 0.77%
2010 60.10M 154.94%
2009 23.57M 8.03%
2008 21.82M -9.98%
2007 24.24M 1.94%
2006 23.78M 26.20%
2005 18.84M 85.90%
2004 10.14M 0.00%
Utestående aksjer for lignende selskaper eller konkurrenter
Selskap Utestående aksjer Forskjell Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M 26.08%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -69.12%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 0.00 -100.00%
BE